USD 0.0
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2021 | 67.62 Million USD | -80.41% |
2020 | 345.18 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2022 Q2 | 62 Million USD | -7.29% |
2022 Q1 | 66.87 Million USD | 0.0% |
2021 FY | 67.62 Million USD | -80.41% |
2021 Q2 | 383.2 Million USD | 0.0% |
2020 FY | 345.18 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AstraZeneca PLC | 61.86 Billion USD | 99.891% |
Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 99.897% |
CSPC Pharmaceutical Group Limited | 1.53 Billion USD | 95.608% |
Novartis AG | 53.19 Billion USD | 99.873% |
PT Kalbe Farma Tbk. | 255.94 Million USD | 73.577% |